Archive for May, 2004

h1

108575731359808518

May 28, 2004

The Drug Research War
“Mention the term ‘outsourcing,’ and drug development probably doesn’t leap to mind. But this market, which is the heart of pharmaceutical and biotech companies, is growing at a yearly clip of 15% to 20%. Right now the lion’s share of the work has gone to U.S. companies that focus on drug research for giants like Pfizer. But now, India and China are angling to get a piece. “

Advertisements
h1

108575317906550592

May 28, 2004

Biotechs struggle as IPOs find cool reception
“Five initial public offerings had trading debuts Thursday, bringing mixed results and a message that biotech certainly isn’t what the doctor ordered for the IPO market. “

h1

108550526479399865

May 25, 2004

The Health-Care Catastrophe That Won’t Happen
Why biotech gains will rein in medical costs. The lesson of info tech

h1

108536826870714617

May 23, 2004

Will U.S. try to circumvent drug firms patent?
:
The furor over Abbott Laboratories’ 400 percent price increase last December of the AIDS drug Norvir has resulted in an unprecedented meeting at the National Institutes of Health to consider circumventing the drug giant’s patent.

h1

108536814561589600

May 23, 2004

Another gene genie out of the bottle
The European Commission has lifted a five-year moratorium on genetically modified produce, by allowing the sale in Europe of one type of modified corn. But the battle by producers of such crops to win governments’ and consumers’ acceptance is far from over

h1

108489431812406235

May 18, 2004

Could patients glean stock tips?: Drug trial participants may be insider trading.
“Patients in clinical trials might be using information about the drug they are taking to trade illegally in pharmaceutical stocks, warns a group of doctors and bioethicists. But they have no idea how prevalent the problem might be.”

h1

108361255295962108

May 3, 2004

Financial Snapshot For March 2004: Looking Good 04/14/2004
“It’s been a rocky first quarter for the biotech stocks – and for the markets in general. Yet, despite investors’ nervousness – about issues as diverse as the terrorist train bombing in Madrid and the departure of Mark McClellan from the FDA – the biotech sector managed to hold its own, and even out-performed the Nasdaq Composite Index.”